Liberty One Investment Management LLC Acquires 1,266 Shares of Amgen Inc. (NASDAQ:AMGN)

Liberty One Investment Management LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 8.5% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 16,161 shares of the medical research company's stock after purchasing an additional 1,266 shares during the period. Liberty One Investment Management LLC's holdings in Amgen were worth $5,035,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Pinney & Scofield Inc. bought a new stake in shares of Amgen during the fourth quarter worth $26,000. First Pacific Financial grew its holdings in shares of Amgen by 304.5% during the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock worth $28,000 after purchasing an additional 67 shares during the last quarter. Ritter Daniher Financial Advisory LLC DE grew its holdings in shares of Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after purchasing an additional 51 shares during the last quarter. Atala Financial Inc bought a new stake in shares of Amgen during the fourth quarter worth $34,000. Finally, Heck Capital Advisors LLC bought a new stake in shares of Amgen during the fourth quarter worth $36,000. Institutional investors own 76.50% of the company's stock.

Analyst Ratings Changes

Several research firms recently issued reports on AMGN. Mizuho raised their price target on Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a report on Wednesday, May 7th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $305.00 price target on shares of Amgen in a report on Tuesday, June 24th. Morgan Stanley reiterated an "equal weight" rating on shares of Amgen in a report on Friday, May 2nd. William Blair reiterated an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. Finally, Guggenheim assumed coverage on Amgen in a report on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 price target on the stock. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $307.82.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the sale, the senior vice president owned 8,162 shares of the company's stock, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.76% of the company's stock.

Amgen Stock Up 1.3%

Amgen stock traded up $3.83 during midday trading on Thursday, reaching $300.35. The stock had a trading volume of 1,381,119 shares, compared to its average volume of 2,844,993. The firm's fifty day simple moving average is $282.95 and its 200-day simple moving average is $287.50. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The stock has a market capitalization of $161.50 billion, a P/E ratio of 27.40, a price-to-earnings-growth ratio of 2.69 and a beta of 0.49. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same quarter last year, the firm earned $3.96 EPS. Amgen's revenue for the quarter was up 9.4% compared to the same quarter last year. As a group, analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.